Contentious Issues in Gout Management: The Story so Far
Mohamed Talaat,1 Kyle Park,1 Naomi Schlesinger2 1Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA; 2Division of Rheumatology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 08903-0019, USACorrespondence: Naomi SchlesingerDepartment of Medicin...
Guardado en:
Autores principales: | Talaat M, Park K, Schlesinger N |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/915a56298e6a4ac88198231cd92d9bb9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Atypical musculoskeletal manifestations of gout in hyperuricemia patients
por: Sakti M, et al.
Publicado: (2019) -
Impact of pegloticase on patient outcomes in refractory gout: current perspectives
por: Cunha RN, et al.
Publicado: (2018) -
Cut-Off Value of Serum Uric Acid for Development of Gout Disease in Patients with Multiple Co-Morbidities
por: Firdevs Ulutaş, et al.
Publicado: (2021) -
Critical appraisal of the role of pegloticase in the management of gout
por: Ea HK, et al.
Publicado: (2012) -
The epidemiology and treatment of gout
por: McGill NW
Publicado: (2011)